# Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy
Canonical URL: https://biopharmsignal.com/news/TCMD/tactile-medical-launches-next-generation-afflovestr-airway-clearance-therapy
Ticker: TCMD
Company: Tactile Systems Technology, Inc.
Source: Tactile Systems Technology, Inc.
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.tactilemedical.com
## Summary

The Investor Relations website contains information about Tactile Systems Technology, Inc. 's business for stockholders, potential investors, and financial analysts.

## Article Body
Reduced Weight, Expanded Size Adjustability, and Built-in Wi-Fi & Bluetooth® Deliver a More Comfortable, Connected Patient Experience Without Compromising Clinical Effectiveness MINNEAPOLIS, June 02, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation (HFCWO) therapy system. The next-generation system maintains its indication for use as a treatment option for chronic neuromuscular and respiratory conditions, including cystic fibrosis and bronchiectasis, across pediatric and geriatric populations, while introducing enhancements to patient comfort, ease of use, and connected care capabilities to support long-term therapy adherence.

“Commercial introduction of the next-generation AffloVest system reflects our ongoing commitment to innovation that improves the lives of patients who depend on our therapies every day, and we are pleased to make our upgraded airway clearance product available ahead of this year’s winter respiratory season,” said Sheri Dodd, Chief Executive Officer of Tactile Medical. “Importantly, the new system preserves the same proven clinical foundation that clinicians trust, while delivering a more comfortable and connected experience, reinforcing AffloVest’s position as a versatile solution for chronic respiratory patients, including those with bronchiectasis, at every stage of life. We designed this new system with the entire care network in mind, from the patient managing their condition to the clinician guiding their care.”

Effective management of chronic respiratory conditions requires a multimodal approach in which airway clearance plays a critical, complementary role alongside other therapies, including pharmacological agents. While these medications target inflammation and infection, they do not directly address retained mucus, one of the primary drivers of impaired lung function and disease progression. HFCWO therapy, including AffloVest, mechanically mobilizes and facilitates removal of secretions to improve ventilation and support overall respiratory health, and published clinical literature demonstrates its ability to enhance mucus transport and reduce secretion burden.

Based on feedback from patients, clinicians, and durable medical equipment (DME) partners, the next-generation AffloVest was intentionally designed with a focus on simplifying setup and improving the overall treatment experience. The new system features a lighter and more adjustable vest than its predecessor to accommodate a broad range of patient ages and body types. Paired with a redesigned controller built for intuitive navigation, AffloVest is now easier to put on, simpler to operate, and more comfortable to wear at home and on the go.

The next-generation AffloVest also offers built-in Wi-Fi and Bluetooth connectivity, enabling patients to visualize their treatment progress and stay engaged with therapy, while equipping clinicians with real-world data needed to have more informed, personalized treatment discussions. DME providers also gain access to therapy utilization data that supports patient care and reimbursement requirements with payers.

About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic inflammatory lung disease by helping them live better and care for themselves. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

Investor Inquiries: Sam Bentzinger Gilmartin Group [email protected]
## Recent Company News
- 2026-07-13 12:00 EST — [Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients](https://biopharmsignal.com/news/TCMD/tactile-medical-enters-exclusive-u-s-distribution-agreement-with-elastimed-for-i-116aea64) — Source: Tactile Systems Technology, Inc.
- 2026-06-25 13:46 EST — [Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy](https://biopharmsignal.com/news/TCMD/tactile-medical-launches-next-generation-afflovestr-airway-clearance-therapy) — Source: Tactile Systems Technology, Inc.
- 2026-06-25 13:46 EST — [Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference](https://biopharmsignal.com/news/TCMD/tactile-medical-to-present-at-the-william-blair-46th-annual-growth-stock-conference) — Source: Tactile Systems Technology, Inc.
- 2026-06-25 13:46 EST — [Tactile Medical to Release Third Quarter of Fiscal Year 2025 Financial Results on November 3, 2025](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-third-quarter-of-fiscal-year-2025-financial-results-on-november-3-2025) — Source: Tactile Systems Technology, Inc.
- 2026-06-25 13:46 EST — [Landmark Study Demonstrates Sustained Clinical Benefits of Flexitouch® Plus as First-Line Therapy in Treating Head and Neck Cancer-Related Lymphedema](https://biopharmsignal.com/news/TCMD/landmark-study-demonstrates-sustained-clinical-benefits-of-flexitouchr-plus-as-first-line-therapy-in-treating-head-and-neck-cancer-related-lymphedema) — Source: Tactile Systems Technology, Inc.
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)